AstraZeneca PLC (ZEGA) - Net Assets
Based on the latest financial reports, AstraZeneca PLC (ZEGA) has net assets worth €45.97 Billion EUR (≈ $53.74 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€114.46 Billion ≈ $133.81 Billion USD) and total liabilities (€68.48 Billion ≈ $80.07 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €45.97 Billion |
| % of Total Assets | 40.16% |
| Annual Growth Rate | 7.6% |
| 5-Year Change | 161.36% |
| 10-Year Change | 120.82% |
| Growth Volatility | 46.44 |
AstraZeneca PLC - Net Assets Trend (2014–2024)
This chart illustrates how AstraZeneca PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AstraZeneca PLC (2014–2024)
The table below shows the annual net assets of AstraZeneca PLC from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €40.87 Billion ≈ $47.78 Billion |
+4.35% |
| 2023-12-31 | €39.17 Billion ≈ $45.79 Billion |
+5.69% |
| 2022-12-31 | €37.06 Billion ≈ $43.32 Billion |
-5.67% |
| 2021-12-31 | €39.29 Billion ≈ $45.93 Billion |
+151.23% |
| 2020-12-31 | €15.64 Billion ≈ $18.28 Billion |
+7.14% |
| 2019-12-31 | €14.60 Billion ≈ $17.06 Billion |
+3.93% |
| 2018-12-31 | €14.04 Billion ≈ $16.42 Billion |
-15.61% |
| 2017-12-31 | €16.64 Billion ≈ $19.46 Billion |
-0.16% |
| 2016-12-31 | €16.67 Billion ≈ $19.49 Billion |
-9.94% |
| 2015-12-31 | €18.51 Billion ≈ $21.64 Billion |
-5.79% |
| 2014-12-31 | €19.65 Billion ≈ $22.97 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to AstraZeneca PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 74.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €3.16 Billion | 7.75% |
| Other Components | €37.63 Billion | 92.25% |
| Total Equity | €40.79 Billion | 100.00% |
AstraZeneca PLC Competitors by Market Cap
The table below lists competitors of AstraZeneca PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Roche Holding AG
SW:ROP
|
$254.60 Billion |
|
Toyota Motor Corporation ADR
NYSE:TM
|
$255.57 Billion |
|
Philip Morris International Inc
NYSE:PM
|
$255.61 Billion |
|
UnitedHealth Group Incorporated
NYSE:UNH
|
$256.27 Billion |
|
Toyota Motor Corporation
MX:TMN
|
$251.65 Billion |
|
Wells Fargo & Company
NYSE:WFC
|
$245.62 Billion |
|
Westpac Banking Corporation
AU:WBCPI
|
$243.39 Billion |
|
Royal Bank of Canada
TO:RY
|
$242.92 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AstraZeneca PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 39,143,000,000 to 40,786,000,000, a change of 1,643,000,000 (4.2%).
- Net income of 7,035,000,000 contributed positively to equity growth.
- Dividend payments of 4,629,000,000 reduced retained earnings.
- Other factors decreased equity by 720,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €7.04 Billion | +17.25% |
| Dividends Paid | €4.63 Billion | -11.35% |
| Other Changes | €-720.00 Million | -1.77% |
| Total Change | €- | 4.20% |
Book Value vs Market Value Analysis
This analysis compares AstraZeneca PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.87x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.39x to 2.87x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €11.81 | €75.50 | x |
| 2018-12-31 | €9.84 | €75.50 | x |
| 2019-12-31 | €10.00 | €75.50 | x |
| 2020-12-31 | €11.90 | €75.50 | x |
| 2021-12-31 | €25.34 | €75.50 | x |
| 2022-12-31 | €23.90 | €75.50 | x |
| 2023-12-31 | €25.25 | €75.50 | x |
| 2024-12-31 | €26.30 | €75.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AstraZeneca PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.25%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.01%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 2.55x
- Recent ROE (17.25%) is above the historical average (14.06%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 6.28% | 4.64% | 0.45x | 2.99x | €-729.70 Million |
| 2015 | 15.28% | 11.43% | 0.41x | 3.25x | €976.00 Million |
| 2016 | 23.56% | 15.21% | 0.37x | 4.21x | €2.01 Billion |
| 2017 | 20.06% | 13.36% | 0.35x | 4.23x | €1.50 Billion |
| 2018 | 17.28% | 9.76% | 0.36x | 4.86x | €908.20 Million |
| 2019 | 10.17% | 5.47% | 0.40x | 4.68x | €22.30 Million |
| 2020 | 20.46% | 12.01% | 0.40x | 4.27x | €1.63 Billion |
| 2021 | 0.29% | 0.30% | 0.36x | 2.68x | €-3.81 Billion |
| 2022 | 8.88% | 7.41% | 0.46x | 2.61x | €-415.70 Million |
| 2023 | 15.21% | 13.00% | 0.45x | 2.58x | €2.04 Billion |
| 2024 | 17.25% | 13.01% | 0.52x | 2.55x | €2.96 Billion |
Industry Comparison
This section compares AstraZeneca PLC's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $27,405,578,833
- Average return on equity (ROE) among peers: 8.42%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AstraZeneca PLC (ZEGA) | €45.97 Billion | 6.28% | 1.49x | $252.57 Billion |
| Bayer AG NA (BAYN) | $33.17 Billion | 3.01% | 2.63x | $44.22 Billion |
| Cosmo Pharmaceuticals N.V (C43) | $489.18 Million | -0.74% | 0.25x | $1.65 Billion |
| CSPC Pharmaceutical Group Limited (CVG) | $31.64 Billion | 19.25% | 0.32x | $10.18 Billion |
| CSPC PHARMACEUT.GR. ADR4 (CVGU) | $31.64 Billion | 19.25% | 0.32x | $11.04 Billion |
| Grifols S.A (G0FB) | $8.46 Billion | 2.46% | 1.55x | $2.02 Billion |
| Sanofi (SNW2) | $59.03 Billion | 7.29% | 0.89x | $105.72 Billion |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo,… Read more